(Q38205291)

31 August 2017

1 reference

title

Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection (English)

1 reference

31 August 2017

main subject

anti-retroviral agent

0 references

author name string

Yarchoan R

series ordinal

1

1 reference

31 August 2017

Mitsuya H

series ordinal

2

1 reference

31 August 2017

Broder S

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 August 1989

1 reference

American Journal of Medicine

31 August 2017

published in

1 reference

31 August 2017

volume

87

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

191-200

1 reference

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Human T-lymphotropic retroviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

HIV infection is blocked in vitro by recombinant soluble CD4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

A soluble CD4 protein selectively inhibits HIV replication and syncytium formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

A soluble form of CD4 (T4) protein inhibits AIDS virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Soluble CD4 molecules neutralize human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Designing CD4 immunoadhesins for AIDS therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

HIV-infected cells are killed by rCD4-ricin A chain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Strategies for antiviral therapy in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Antiviral activity of 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine) against human immunodeficiency virus in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

The trans-activator gene of HTLV-III is essential for virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Resumption of HIV antigen production during continuous zidovudine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Retroviruses and mouse embryos: a rapid model for neurovirulence and transplacental antiviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Suppression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Azidothymidine in the treatment of AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Cytokines alter production of HIV-1 from primary mononuclear phagocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980696-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(89)80696-5

1 reference

31 August 2017

1 reference